The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ligand Pharmaceuticals

Criteria

Inclusion Criteria:

• Postmenopausal women over 50 years who have low bone mineral density.

Exclusion Criteria:

• Women who are under 50 years of age, are premenopausal, or who currently have osteoporosis are excluded.